Skip to main content
Premium Trial:

Request an Annual Quote

Fisher Scientific Stock Drops 5.6 Percent on News of Acquisitions, Q2 Earnings

NEW YORK, Aug. 4 (GenomeWeb News) - Shares in Fisher Scientific were down 5.57 percent, or $3.67, at $62.25 in mid-afternoon trading one day after the company reported strong second-quarter revenue growth, and that it would acquire cellular imaging company Cellomics.


As GenomeWeb News reported, Fisher will acquire Cellomics for $49 million in cash, and testing lab Lancaster Laboratories for $150 million in cash, the company said yesterday.


Fisher said that it will closely collaborate with Carl Zeiss Jena, Cellomics' largest shareholder, in the high-content screening field. Cellomics had $13 million in revenues in 2004.


Yesterday Fisher posted an increase in second-quarter revenues of 33 percent to $1.4 billion, from $1 billion during the year-ago quarter. Excluding currency effects, organic revenues grew by 5.2 percent. Sales of scientific products and services accounted for 74 percent of total revenues this quarter.


The company had a net income this quarter of $101.4 million, or $.80 per share, more than double last year's $44.7 million, or $.64 per share, during the same period. This quarter's income included $16 million associated with discontinued operations, among them the sale of Atos Medical.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.